- Home
- FMAO vs QURE Comparison
FMAO vs QURE Comparison
Compare FMAO & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FMAO
- QURE
- Stock Information
- Founded
- FMAO 1897
- QURE 1998
- Country
- FMAO United States
- QURE Netherlands
- Employees
- FMAO N/A
- QURE N/A
- Industry
- FMAO Savings Institutions
- QURE Biotechnology: Pharmaceutical Preparations
- Sector
- FMAO Finance
- QURE Health Care
- Exchange
- FMAO Nasdaq
- QURE Nasdaq
- Market Cap
- FMAO 377.5M
- QURE 432.6M
- IPO Year
- FMAO N/A
- QURE 2007
- Fundamental
- Price
- FMAO $30.81
- QURE $7.33
- Analyst Decision
- FMAO Hold
- QURE Buy
- Analyst Count
- FMAO 2
- QURE 6
- Target Price
- FMAO $26.00
- QURE $17.00
- AVG Volume (30 Days)
- FMAO 23.7K
- QURE 699.6K
- Earning Date
- FMAO 10-30-2024
- QURE 11-05-2024
- Dividend Yield
- FMAO 2.81%
- QURE N/A
- EPS Growth
- FMAO N/A
- QURE N/A
- EPS
- FMAO 1.68
- QURE N/A
- Revenue
- FMAO $98,003,000.00
- QURE $28,587,000.00
- Revenue This Year
- FMAO N/A
- QURE $178.43
- Revenue Next Year
- FMAO $7.11
- QURE $49.15
- P/E Ratio
- FMAO $19.14
- QURE N/A
- Revenue Growth
- FMAO N/A
- QURE N/A
- 52 Week Low
- FMAO $17.29
- QURE $3.73
- 52 Week High
- FMAO $32.84
- QURE $11.35
- Technical
- Relative Strength Index (RSI)
- FMAO 66.79
- QURE 61.28
- Support Level
- FMAO $27.05
- QURE $5.35
- Resistance Level
- FMAO $32.84
- QURE $7.28
- Average True Range (ATR)
- FMAO 0.95
- QURE 0.50
- MACD
- FMAO 0.40
- QURE 0.04
- Stochastic Oscillator
- FMAO 68.62
- QURE 85.75
About FMAO Farmers & Merchants Bancorp Inc.
Farmers & Merchants Bancorp Inc is a holding company for Farmers & Merchants Bank of Central California. The company is engaged in general commercial banking business. The activities of the company include commercial, agricultural and residential mortgages as well as consumer and credit card lending activities.
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.